
MOBI Stock Forecast & Price Target
MOBI Analyst Ratings
Bulls say
Mobia Medical is supported by a rare first-mover advantage as the first and only FDA-approved VNS platform for chronic ischemic stroke recovery, addressing a large unmet need among roughly 9 million ischemic stroke survivors. Clinical evidence is strengthening, with the VNS-REHAB study showing 76% of participants achieved a clinically meaningful response, average FMA-UE gains of +7.5 points, and durable improvements that continued between years one and two. Commercial traction is also accelerating, as 2Q26 revenue reached $13.5 million, up 102% year over year, with active territories rising to about 35.5 and management guiding FY26 sales of $54 million to $56 million.
Bears say
Mobia Medical is exposed to meaningful execution risk because its valuation depends almost entirely on adoption of Vivistim, and slower uptake by fewer new stroke centers than modeled would directly weaken revenue growth. Additional pressure could come from lower overall market growth rates and faster ASP degradation than assumed, which would compress sales and margins since the company generates all of its revenue from Vivistim system sales. The outlook is further challenged by longer product development timelines and higher operating expense spend than modeled, both of which could delay profitability and increase cash burn.
This aggregate rating is based on analysts' research of Mobia Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
MOBI Analyst Forecast & Price Prediction
Start investing in MOBI
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Mobia Medical Inc (MOBI) Forecast
MOBI Analyst Forecast & Price Prediction
Start investing in MOBI
Order type
Buy in
Order amount
Est. shares
0 shares